AKBA - アケビア・セラピュ―ティクス (Akebia Therapeutics Inc.) アケビア・セラピュ―ティクス

 AKBAのチャート


 AKBAの企業情報

symbol AKBA
会社名 Akebia Therapeutics Inc (アケビア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アケビ・セェラァピュゥーティィクス(Akebia Therapeutics Inc.)はバイオ医薬品企業である。同社は低酸素誘導性因子(HIF)の生物学に基づいた治療薬の開発と商品化に従事する。同社の主力な候補製品のバダデュスタットは、慢性腎疾患(CKD)における貧血の治療に適応される。同社は経口療法におけるバダダスタットの開発を行う。バダスタットは、CKDの貧血の治療のためのフェーズⅢ開発におけるHIF-プロリルヒドロキシラーゼ(HIF-PH)阻害剤である。また、同社は疾患を標的とするHIFベースの候補製品のポートフォリオの開発に従事する。同社のポートフォリオは、社内で開発された候補製品のAKB-6899、ライセンス取得済みの候補製品のAKB-5169を含む。AKB-5169は、炎症性腸疾患(IBD)のための経口治療として開発中の前臨床化合物である。   アケビア・セラピュ―ティクスは米国のバイオ医薬品会社。低酸素誘導因子、HIF、生物学と腎臓病の患者用製品の商品化に基づく独自の治療法の開発に焦点を当てる。 「HIF」は体内で赤血球の生産と貧血を治療する。「AKB-6548」は一日一回の経口療法、「AKB-6548」は安定的にヘモグロビンレベルを上昇させる。本社はマサチュ―セッツ州ケンブリッジ。   Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
本社所在地 245 First Street Suite 1100 Cambridge MA 02142 USA
代表者氏名 Muneer A. Satter ムネア・サッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-871-2098
設立年月日 39114
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 114人
url www.akebia.com
nasdaq_url https://www.nasdaq.com/symbol/akba
adr_tso
EBITDA EBITDA(百万ドル) -72.19200
終値(lastsale) 8.59
時価総額(marketcap) 490029976.17
時価総額 時価総額(百万ドル) 484.88320
売上高 売上高(百万ドル) 223.32200
企業価値(EV) 企業価値(EV)(百万ドル) 82.76020
当期純利益 当期純利益(百万ドル) -68.34100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akebia Therapeutics Inc revenues increased 92% to $94.7M. Net loss decreased 13% to $57.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 72% to $1.4M (expense) Interest income increase from $1M to $2.6M (income) Other Non Rec.

 AKBAのテクニカル分析


 AKBAのニュース

   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   Akebia Therapeutics to Report Second Quarter 2020 Financial Results  2020/08/03 12:00:00 PR Newswire
CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report its financial results for the second quarter ended June 30, 2020…
   Akebia Initiates Vadadustat Study In Covid-19 Patients  2020/07/14 14:32:55 Smarter Analyst
Akebia Therapeutics (AKBA) has announced the initiation of an investigator-sponsored study evaluating the use of vadadustat as a potential therapy to prevent and … The post Akebia Initiates Vadadustat Study In Covid-19 Patients appeared first on Smarter Analyst .
   Akebia launches vadadustat study in COVID-19 complication (NASDAQ:AKBA)  2020/07/14 13:56:14 Seeking Alpha
Akebia Therapeutics (AKBA -0.2%) has initiated an investigator-sponsored study evaluating the use of vadadustat, an investigational oral hypoxia-inducible
   The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy  2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   Akebia Therapeutics to Report Second Quarter 2020 Financial Results  2020/08/03 12:00:00 PR Newswire
CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report its financial results for the second quarter ended June 30, 2020…
   Akebia Initiates Vadadustat Study In Covid-19 Patients  2020/07/14 14:32:55 Smarter Analyst
Akebia Therapeutics (AKBA) has announced the initiation of an investigator-sponsored study evaluating the use of vadadustat as a potential therapy to prevent and … The post Akebia Initiates Vadadustat Study In Covid-19 Patients appeared first on Smarter Analyst .
   Akebia launches vadadustat study in COVID-19 complication (NASDAQ:AKBA)  2020/07/14 13:56:14 Seeking Alpha
Akebia Therapeutics (AKBA -0.2%) has initiated an investigator-sponsored study evaluating the use of vadadustat, an investigational oral hypoxia-inducible
   The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy  2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.
   Akebia Therapeutics to Present at RBC Capital Markets Global Healthcare Virtual Conference  2020/05/08 12:00:00 PR Newswire
CAMBRIDGE, Mass., May 8, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will participate…
   Akebia Spikes 38% On Positive Readout for Pivotal Trial; And Further Upside Lies Ahead  2020/05/06 05:49:49 Smarter Analyst
Biopharma Akebia Therapeutics (AKBA) skyrocketed 38% in Tuesday’s trading after reporting positive topline data from the global Phase 3 clinical trials of vadadustat. … The post Akebia Spikes 38% On Positive Readout for Pivotal Trial; And Further Upside Lies Ahead appeared first on Smarter Analyst .
   Akebia Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation  2020/05/05 12:41:58 Seeking Alpha
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with their 2020 Q1 earnings call.
   Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results  2020/05/05 11:30:00 PR Newswire
CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced positive top-line results from INNO2VATE, its global Phase 3 cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, its investigational oral hypoxia-inducible…
   Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients  2020/05/05 11:01:00 Business Wire
ST GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anaemia due to Chronic Kidney Disease (CKD) in adult dialysis-dependent pa

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アケビア・セラピュ―ティクス AKBA Akebia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)